Helius Medical Technologies Faces Delisting Concerns

TL;DR

Helius Medical Technologies might be getting delisted, check exchange rules.

AI Summary

Helius Medical Technologies, Inc. filed an 8-K on February 7, 2025, to report a notice of delisting or failure to satisfy continued listing rules, a transfer of listing, and other events. The filing also covers shareholder nominations pursuant to Exchange Act Rule 14a-11.

Why It Matters

This filing indicates potential issues with Helius Medical Technologies' compliance with stock exchange listing standards, which could impact its stock's tradability and investor confidence.

Risk Assessment

Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's stock trading and overall financial health.

Key Players & Entities

• HELIUS MEDICAL TECHNOLOGIES, INC. (company) — Registrant
• 0001558370-25-000717 (filing_id) — Accession Number
• February 7, 2025 (date) — Report Date
• 642 Newtown Yardley Road, Suite 100 Newtown, PA 18940 (address) — Company Business Address

FAQ

Key Financial Figures

• $0.001 — hich registered Class A Common Stock, $0.001 par value HSDT The Nasdaq Stock Mar
• $1.00 — ice for its common stock had been below $1.00 per share for 30 consecutive trading da
• $0.751 — gregate, at a reduced exercise price of $0.751 per share, in exchange for the Company'

Filing Documents

• hsdt-20250207x8k.htm (8-K) — 44KB
• hsdt-20250207x8k001.jpg (GRAPHIC) — 7KB
• 0001558370-25-000717.txt ( ) — 182KB
• hsdt-20250207.xsd (EX-101.SCH) — 3KB
• hsdt-20250207_lab.xml (EX-101.LAB) — 16KB
• hsdt-20250207_pre.xml (EX-101.PRE) — 10KB
• hsdt-20250207x8k_htm.xml (XML) — 5KB

01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously reported, on August 9, 2024, Helius Medical Technologies, Inc. (the "Company") received a letter (the "Bid Price Deficiency Notice") from the Listing Qualifications Department (the "Staff") of the Nasdaq Stock Market ("Nasdaq") notifying the Company that, because the closing bid price for its common stock had been below $1.00 per share for 30 consecutive trading days, it was not compliant with Nasdaq Marketplace Rule 5550(a)(2) (the "Minimum Bid Price Requirement"). In accordance with Nasdaq Marketplace Rule 5810(c)(3)(A), the Company has a period of 180 calendar days from August 9, 2024, or until February 5, 2025, to regain compliance with the Minimum Bid Price Requirement. On February 7, 2025, the Company received a letter from the Staff indicating the Company's continued non-compliance with the Minimum Bid Price Requirement. The letter further informed the Company that the Company's common stock would be delisted from The Nasdaq Capital Market unless the Company appeals the Staff's delisting determination by requesting a hearing before the Nasdaq Hearings Panel (the "Panel"). The Company's request for a hearing will stay any further delisting action by the Staff pending the ultimate outcome of the hearing. The Company's common stock will remain listed and eligible for trading on Nasdaq at least pending the ultimate conclusion of the hearing process. The Company intends to timely request a hearing before the Panel to appeal the determination by the Staff, and to present its plan to regain and sustain compliance with the Minimum Bid Price Requirement. There can be no assurance that the Company will ultimately regain compliance and remain listed on Nasdaq.

08 Shareholder Director Nominations

Item 5.08 Shareholder Director Nominations. The information in Item 8.01 of this Current Report on Form 8-K is incorporated by reference into this Item 5.08, to the extent applicable.

01 Other Events

Item 8.01 Other Events. As previously disclosed, on January 21, 2025, the Company entered into warrant exercise inducement offer letters (the "Inducement Letters") with certain holders (the "Holders") of its existing Series A warrants and Series B warrants to purchase shares of the Company's Class A common stock (the "Existing Warrants"), pursuant to which the Holders agreed to exercise for cash their Existing Warrants to purchase an aggregate of 4,971,110 shares of the Company's common stock, in the aggregate, at a reduced exercise price of $0.751 per share, in exchange for the Company's agreement to issue new Series C Warrants and Series D Warrants (the "Inducement Warrants") on substantially the same terms as the Existing Warrants described below, to purchase up to 6,213,888 shares of the Company's common stock (the "Inducement Warrant Shares"). The exercise of the Inducement Warrants and issuance of the Inducement Warrant Shares is subject to stockholder approval in accordance with Nasdaq Listing Rule 5635(d) of The Nasdaq Stock Market LLC (the "Stockholder Approval"). The Company agreed to hold an annual or special meeting of stockholders on or prior to the date that is ninety (90) calendar days following the date of the Inducement Letters for the purpose of obtaining such Stockholder Approval pursuant to, with the recommendation of the Company's board of directors that such proposal is approved. In connection with the foregoing, the Company expects to hold its 2025 Annual Meeting of Stockholders (the "Annual Meeting") on Monday, April 21, 2025 and has fixed the closing of business on March 12, 2025 as the record date for the Annual Meeting. Because the date of the Annual Meeting has been changed by more than 30 days from the anniversary date of the 2024 Annual Meeting of Stockholders, the Company is providing the due date for submission of any qualified stockholder proposal. 2 Pursuant to applicable Securities and Exchange Commission ("SEC") rules and

View Full Filing

View this 8-K filing on SEC EDGAR